OBJECTIVE:
The obstetric comorbidity index (OBCMI) is a claimsdata derived maternal risk-assessment tool that summarizes the burden of maternal comorbidities into a single numerical score. Though validated in external database populations, the clinical utility of the score to triage high-risk women at risk of adverse outcomes has yet to be explored. The aim of this study was to prospectively validate a clinical modification of the OBCMI as a maternal risk assessment tool for predicting severe maternal morbidity (SMM). STUDY DESIGN: All patients with pregnancies at or beyond 23 weeks gestation presenting to labor and delivery (L&D) from February to June 2018 were included in the study. The admitting L&D nurse assessed patient comorbidities and calculated the patient's OBCMI (Table) . The score was recalculated at each 12-hour shift change. A multidisciplinary panel of clinicians determined whether patients experienced SMM based on the ACOG/SMFM consensus definition, blinded to the patient's OBCMI score. We analyzed association between the OBCMI score and the occurrence of SMM and calculated a c-statistic to define the discrimination of the score. RESULTS: Two thousand ninety-one women were included, of whom 1.75% developed SMM (n¼40). The prevalence of the individual comorbidities comprising the score are presented in the Table. The median OBCMI score for women experiencing the primary outcome was 5 (IQR 2.0-7.5) compared to a median score of 1 (IQR 0-3) for those without SMM (p<0.01). The frequency of SMM increased from 0.39% for those with a score of 0 to 21.4% for those with a score greater than or equal to 9 ( Figure) . For every one point increase in the score patients experienced a 1.53 increase in odds of SMM (95% CI 1.39-1.69). The c-statistic for the OB-CMI score was 0.80. CONCLUSION: The OBCMI score can prospectively identify women at risk of severe maternal morbidity in a clinical setting. Routine use of the OBCMI score has the potential to identify at-risk women warranting increased surveillance or transfer of care in an attempt to prevent adverse maternal outcomes.
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The APOSTEL-III study was a multicenter RCT that compared atosiban and nifedipine in women with threatened preterm birth (Van Vliet et al, Lancet 2016). The primary outcome, a composite of neonatal short term morbidity and mortality was comparable between the two arms.
We sought to compare the long-term effects of tocolysis with atosiban or nifedipine on health and development of children. STUDY DESIGN: The APOSTEL III study randomized 505 women in 19 Dutch and Belgian hospitals. Five years later, we asked all participants to complete four questionnaires.
Main outcome measures were neurological and behavioral development at the age of 2.5-5.5 years. The three developmental questionnaires are divided in subscales that cover a specific domain of child development, expressed in scores standardized for age and sex. The children in the atosiban and nifedipine groups were compared by calculating T-scores, thus identifying infants with substandard scores. Additionally, a questionnaire regarding general health was used. Exclusion criteria were: infants older than 66 months, no surviving infant, participant not traceable or refusal of participance. RESULTS: Of the 370 women eligible for follow up, 194 (52%) women returned the questionnaires, encompassing data of 108 infants to atosiban and 114 infants randomized to nifedipine. Baseline characteristics did not differ between both groups with respect to responders vs non-responders as well as within the treatment arms in the responding group. Developmental outcome as measured by the ASQ-3, BRIEF-P, CBCL and general health questionnaires, is shown in Table 1 . Overall, there were no significant differences between the groups.
Total developmental delay did not differ between the atosiban and nifedipine and group (34.3 % vs 28.9 %, OR 1.28; 95% CI 0.73-2.26). However, a difference was found in the subdomain problem solving (21.3 % vs 9.6%, OR 2.53; 95% CI 1.17-5.49). We performed a sensitivity analysis by including neonatal deaths, all scoring substandard. This showed no group difference in substandard scores (26.1 % vs 20.8%, OR 1.35; 95% CI 0.74-2.44).
Executive function disorders were similar (12.0 vs 11.4%, OR 1.06; 95% CI 0.47-2.41) as well as behavioral problems (6.5% vs 8.8%, OR 0.72; 95% CI 0.26-1.97). No differences in general health were found. CONCLUSION: In this long-term follow-up study of tocolysis, outcomes on broad child development and behavior were not different between atosiban and nifedipine exposed children.
